title: Economic evaluation of donepezil treatment for Alzheimer's disease in Japan.
abstract: To demonstrate the economic impact of donepezil treatment for patients with mild to moderate Alzheimer's disease (AD) in Japanese clinical settings, we conducted a cost-utility analysis using the Markov model. This analysis was made from a payer's perspective, and the cost was estimated based on the fee schedule of the Japanese national health insurance and the long-term care insurance. The results of the clinical trial of donepezil on AD in Japan were used to estimate the drug efficacy. Under the base-case analysis with a 2-year time horizon, donepezil treatment for patients with mild to moderate AD was considered to be an economically dominant strategy compared to conventional therapy.
authors.affiliation: Department of Health Policy and Management, Keio University School of Medicine, Tokyo, Japan. shunya@post.harvard.edu
authors.forename: Shunya
authors.initials: S
authors.lastname: Ikeda
authors.forename: Yukari
authors.initials: Y
authors.lastname: Yamada
authors.forename: Naoki
authors.initials: N
authors.lastname: Ikegami
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy / Q000191:economics*; D017326:Clinical Trials, Phase III as Topic; D003362:Cost-Benefit Analysis; D000077265:Donepezil; D016527:Drug Costs; D005245:Fee Schedules; D006291:Health Policy / Q000191:economics*; D006801:Humans; D007189:Indans / Q000191:economics* / Q000627:therapeutic use; D007564:Japan; D008390:Markov Chains; D018697:Nootropic Agents / Q000191:economics* / Q000627:therapeutic use; D010880:Piperidines / Q000191:economics* / Q000627:therapeutic use; D011788:Quality of Life; D019057:Quality-Adjusted Life Years; D012720:Severity of Illness Index
chemical_list: D007189:Indans; D018697:Nootropic Agents; D010880:Piperidines; D000077265:Donepezil